MarketIQ Analyst Report for Madison Square Garden Sports Corp

TWO PENNSYLVANIA PLAZA, NEW YORK, NY, US
MSGS

Last Updated: 08 Nov 2024

Executive Summary

Madison Square Garden Sports Corp. (MSGS) is a publicly traded company that owns and operates the New York Knicks (NBA), New York Rangers (NHL), and New York Liberty (WNBA) professional sports teams, as well as the Madison Square Garden arena in New York City. The company's stock is currently trading at $227.38, with a market capitalization of $5.48 billion.

Company Overview

MSGS was founded in 1999 as a spin-off from Cablevision Systems Corporation. The company's primary business is the ownership and operation of professional sports teams and venues. MSGS also generates revenue from ticket sales, concessions, merchandise sales, and media rights.

Fundamental Analysis

MSGS has a strong financial profile, with revenue of $1.04 billion and EBITDA of $155.4 million for the fiscal year ended June 2023. The company's profit margin is 6.8%, and its return on assets is 6.9%. MSGS has a strong balance sheet, with $1.1 billion in cash and equivalents and $1.3 billion in debt.

Technical Analysis

The technical analysis of MSGS shows that the stock is currently in a bullish trend. The stock price has been trading above its 50-day and 200-day moving averages for the past several months. The relative strength index (RSI) is also above 50, indicating that the stock is overbought.

Short Term Outlook

The short-term outlook for MSGS is positive. The company's financial performance is strong, and the stock price is in a bullish trend. The stock is currently trading near its 52-week high, and it is likely to continue to rise in the short term.

Long Term Outlook

The long-term outlook for MSGS is also positive. The company is well-positioned to benefit from the continued growth of the sports industry. The company's strong financial profile and its ownership of iconic sports teams and venues give it a competitive advantage in the market.

Analyst Recommendations

The majority of analysts who cover MSGS recommend buying the stock. The average analyst price target for MSGS is $255.6, which is 12.4% above the current stock price. Overall MSGS is a well-managed company with a strong financial profile and a positive long-term outlook. The stock is currently trading at a fair valuation, and it is likely to continue to rise in the future.